JPMorgan raised the firm’s price target on Genmab (GMAB) to DKK 1,650 from DKK 1,500 and keeps a Neutral rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab A/S Updates Articles of Association to Boost Financial Flexibility
- Genmab Announces Capital Increase Following Employee Warrant Exercise
- Genmab price target raised to DKK 1,900 from DKK 1,750 at Deutsche Bank
- Genmab receives FDA Breakthrough Therapy Designation for rinatabart sesutecan
- Genmab’s Strategic Growth and Clinical Advancements: A Compelling Investment Opportunity